These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 16971739)

  • 41. [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
    Li SF; Wang X; Wang C; He LH; Shi YH; Hao CF; Dong GL; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):944-6. PubMed ID: 19174000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
    Wang J; Fan Y; Xu B
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):597-603. PubMed ID: 20490795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
    Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B
    Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.
    Di Seri M; De Sanctis R; Quadrini S; Adua D; Stumbo L; Del Signore E; Gori B; Grassi P; Basile ML; Longo F
    J Chemother; 2011 Apr; 23(2):110-3. PubMed ID: 21571629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Capecitabine-docetaxel combination treatment.
    Mandelblat J; Bashir T; Budman DR
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1169-78. PubMed ID: 17020452
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Capecitabine: fulfilling the promise of oral chemotherapy.
    Hwang JJ; Marshall JL
    Expert Opin Pharmacother; 2002 Jun; 3(6):733-43. PubMed ID: 12036413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Taxanes and capecitabine in combination: rationale and clinical results.
    Maher JF; Villalona-Calero MA
    Clin Breast Cancer; 2002 Jan; 2(4):287-93. PubMed ID: 11899360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
    Reichardt P; Von Minckwitz G; Thuss-Patience PC; Jonat W; Kölbl H; Jänicke F; Kieback DG; Kuhn W; Schindler AE; Mohrmann S; Kaufmann M; Lück HJ
    Ann Oncol; 2003 Aug; 14(8):1227-33. PubMed ID: 12881384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
    Liu XH; Man YN; Cao R; Liu C; Wu XZ
    Curr Med Res Opin; 2014 Jun; 30(6):1017-24. PubMed ID: 24528110
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
    Tripathy D
    Oncologist; 2007 Apr; 12(4):375-89. PubMed ID: 17470680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
    Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients.
    Frances N; Woloch C; Marouani H; Mercier C; Iliadis A
    Curr Top Med Chem; 2012; 12(15):1665-8. PubMed ID: 22978334
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Capecitabine: new indication. In breast cancer: inadequately assessed.
    Prescrire Int; 2003 Aug; 12(66):123-4. PubMed ID: 12906018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
    Clemons M; Joy AA; Abdulnabi R; Kotliar M; Lynch J; Jordaan JP; Iscoe N; Gelmon K
    Breast Cancer Res Treat; 2010 Nov; 124(1):177-86. PubMed ID: 20814815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.
    O'Shaughnessy JA; Kaufmann M; Siedentopf F; Dalivoust P; Debled M; Robert NJ; Harbeck N
    Oncologist; 2012; 17(4):476-84. PubMed ID: 22418569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.